On May 7, 2014, Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) entered into a Development and Commercialization Agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test for use in the Company’s clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400, the Company’s lead drug candidate. The Agreement provides for the development and subsequent commercialization by Abbott Molecular of a companion diagnostic test utilizing polymerase chain reaction technology to identify with high sensitivity and specificity the presence in tumor biopsy samples of the oncogenic mutation referred to scientifically as MYD88 L265P. The Agreement is effective as of May 1, 2014. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) weekly performance is -0.97%. On last trading day company shares ended up $3.07. Analysts mean target price for the company is $7.00. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) distance from 50-day simple moving average (SMA50) is -1.76%.
Sangamo Biosciences Inc. (NASDAQ:SGMO) SVP Philip D. Gregory sold 15,000 shares of the company’s stock on the open market in a transaction dated Monday, June 2nd. The stock was sold at an average price of $12.85, for a total transaction of $192,750.00. Following the completion of the transaction, the senior vice president now directly owns 109,347 shares in the company, valued at approximately $1,405,109. Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares advanced 7.91% in last trading session and ended the day on $14.18. SGMO return on assets is -17.90%.Sangamo Biosciences, Inc. (NASDAQ:SGMO) quarterly performance is -38.24%.
XOMA Corp (NASDAQ:XOMA) on 9 may posted a loss of 23 cents per share, wider than the Zacks Consensus Estimate of a loss of 19 cents per share and the year-ago loss of 15 cents per share. XOMA Corp (NASDAQ:XOMA) shares moved up 7.56% in last trading session and was closed at $4.41, while trading in range of $4.09 – $4.44. XOMA Corp (NASDAQ:XOMA) year to date (YTD) performance is -34.47%.
Shares of PTC Therapeutics (NASDAQ:PTCT) , a biopharmaceutical company focused on developing oral, small-molecule drugs targeted at genetic disorders, exploded to the upside by as much as 11% after receiving positive commentary from research firm Credit Suisse. PTC Therapeutics, Inc. (NASDAQ:PTCT) ended the last trading day at $24.28. Company weekly volatility is calculated as 7.79% and price to cash ratio as 2.96.PTC Therapeutics, Inc. (NASDAQ:PTCT) showed a positive weekly performance of 4.43%.
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) COO John Duncan Higgons sold 7,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $34.47, for a total value of $241,290.00. Following the completion of the sale, the chief operating officer now directly owns 193,090 shares in the company, valued at approximately $6,655,812. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) weekly performance is 14.62%. On last trading day company shares ended up $40.85. Analysts mean target price for the company is $58.00. Agios Pharmaceuticals Inc. (NASDAQ:AGIO) distance from 50-day simple moving average (SMA50) is 5.21%.